Glaucoma drainage devices aid in controlling IOP by redirecting aqueous from the anterior chamber to an external reservoir to regulate flow. While effective, they are traditionally anchored through the use of sutures, which is both time-intensive and may cause complications.
Recently, evidence has been accumulating to support the theory that cerebrospinal fluid pressure (CSFp) is also important in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG), and the relationship has potential implications for clinical practice, said R. Rand Allingham, MD.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
When I was a resident at the SUNY College of Optometry, I was asked a to conduct a few patient question and answer sessions regarding glaucoma. The sessions consisted of me sitting with a small group of patients, family members, or whoever wanted to know more about glaucoma.
A newly released hand-held tonometer model (Icare ic100, Icare U.S.A.) features several design upgrades while retaining the rebound technology for measuring IOP that was at the core of the earlier model.
Failure to follow-up after ophthalmology appointments can damage patients’ health, a new study suggests. “In our view, national consideration should be given to create targets for reporting how well providers are managing follow-up patients,” reported A Davis and colleagues in the journal Eye.
A silicone punctal plug-based delivery system for ophthalmic medications (Evolute, Mati Therapeutics) provides precisely controlled medication release into the tear film and has been associated with positive results in initial clinical testing.
A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.